)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Ipsen
Ipsen (IPN) investor relations material
Ipsen Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary22 Oct, 2026
Executive summary
Q3 sales reached €1,173.9m, up 26.7% at CER; YTD sales were €3,364.2m, up 24.6% at CER and 23.0% as reported.
Strong core-portfolio growth supported upgraded FY 2026 sales-growth and core operating-margin guidance.
Late-stage pipeline and recent acquisitions expanded potential catalysts across Oncology, Rare Disease and Neuroscience.
Financial highlights
Q3 Core Portfolio sales were €793m, up 23.3%; YTD sales were €2,297m, up 24.2%.
YTD therapy-area sales: Oncology €2,196.9m, up 16.3%; Rare Disease €498.2m, up 100.1%; Neuroscience €669.1m, up 18.8% at CER.
YTD medicine sales included Somatuline €1.067B, up 25.5%; Cabometyx €523m, up 15.6%; Iqirvo €283m, up 170.8%; and Bylvay €189m, up 43.8%.
Currency reduced YTD sales growth by 1.6 percentage points.
Outlook and guidance
FY 2026 sales-growth guidance rose to ~23.0% at CER from >20.0%; core operating-margin guidance increased to ~39.0% of sales from >37.0%.
October exchange rates imply an adverse currency impact of ~0.5% on total sales; guidance assumes Somatuline growth despite expected generic lanreotide entry in Q4.
Management expects 2027 margin to decline from the exceptional 2026 level due to mix, Somatuline erosion, and launch and development investment; margins are expected to remain significant in the midterm.
Iqirvo’s sales ambition increased from >€500m to €1B, with lower-ALP patients representing a significant expansion opportunity.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Ipsen
- H1 2026 sales up 23.5% at CER, core margin rises, and FY guidance upgraded above 20% growth.IPN
Q2 2026 - Q1 2026 sales up 22.6% at CER, led by Rare Disease and robust pipeline progress.IPNQ1 2026 TU
- Double-digit sales and profit growth, strong margins, and robust pipeline support 2026 outlook.IPNH2 2025
- Upgraded 2025 guidance follows 12.1% sales growth and major pipeline advances.IPNQ3 2025 TU
- Double-digit sales and profit growth in H1 2025, with upgraded full-year guidance.IPNH1 2025
- YTD sales up 9.2% to €2,496m; guidance raised amid strong launches and robust segment growth.IPNQ3 2024 TU
- Sales up 9.5% at CER, strong launches, and upgraded guidance with robust cash flow.IPNH1 2024
- Q1 2025 sales up 11.6%, guidance confirmed, and pipeline and financing milestones achieved.IPNQ1 2025 TU
- 2024 sales up 9.9%, core margin 32.6%, with robust pipeline and €2.3B for innovation.IPNH2 2024
Next Ipsen earnings date
Q4 20264 Feb, 2027
Ipsen
Next Ipsen earnings date
Q4 20264 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Ipsen S.A. is a global biopharmaceutical company focused on developing and commercializing innovative therapies in the areas of oncology, rare diseases, and neuroscience. The company’s portfolio includes a range of specialty care products aimed at improving patient outcomes in these therapeutic areas. Ipsen’s research and development efforts emphasize cutting-edge treatments, particularly in areas of high unmet medical need. In addition to its core pharmaceutical activities, Ipsen also operates in consumer healthcare, offering a range of over-the-counter products to support general health and wellness. The company is headquartered in Boulogne-Billancourt, France, and its shares are listed on the Euronext Paris.